AbbVie, Thermo Fisher Scientific, Vertex Pharmaceuticals, BioNTech, and Cencora are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of ABBV stock traded up $5.59 during trading hours on Friday, reaching $185.96. The stock had a trading volume of 10,480,961 shares, compared to its average volume of 6,045,510. The firm has a 50-day simple moving average of $196.85 and a 200-day simple moving average of $187.18. The firm has a market capitalization of $328.96 billion, a PE ratio of 77.48, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. AbbVie has a twelve month low of $153.58 and a twelve month high of $218.66.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Thermo Fisher Scientific stock traded down $2.64 during trading hours on Friday, hitting $424.02. 2,698,284 shares of the company traded hands, compared to its average volume of 1,743,532. The firm has a market cap of $160.06 billion, a P/E ratio of 25.65, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a 1-year low of $409.85 and a 1-year high of $627.88. The firm's 50-day simple moving average is $487.28 and its two-hundred day simple moving average is $527.17.
Read Our Latest Research Report on TMO
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
NASDAQ:VRTX traded up $1.37 during mid-day trading on Friday, reaching $493.84. 1,561,491 shares of the stock were exchanged, compared to its average volume of 1,337,381. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The firm has a market capitalization of $126.81 billion, a PE ratio of -224.47, a PEG ratio of 2.11 and a beta of 0.50. The business has a fifty day moving average price of $489.78 and a 200 day moving average price of $466.35. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.
Read Our Latest Research Report on VRTX
BioNTech (BNTX)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Shares of NASDAQ:BNTX traded down $18.52 on Friday, reaching $102.02. 6,438,309 shares of the company traded hands, compared to its average volume of 899,284. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market capitalization of $24.48 billion, a PE ratio of -48.58 and a beta of 1.07. The company's 50 day moving average is $101.72 and its 200-day moving average is $110.60. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.
Read Our Latest Research Report on BNTX
Cencora (COR)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Shares of NYSE:COR traded up $3.66 during midday trading on Friday, reaching $286.05. The company had a trading volume of 1,815,757 shares, compared to its average volume of 1,522,859. The company has a fifty day simple moving average of $268.09 and a two-hundred day simple moving average of $249.35. The firm has a market cap of $55.47 billion, a price-to-earnings ratio of 40.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora has a 1-year low of $214.77 and a 1-year high of $296.65.
Read Our Latest Research Report on COR
Featured Stories
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
